ArticleAmerican journal of translational research2023
Therapeutic effect of modified Xiaoqinglong Decoction on cough-variant asthma and immunological functioning in children.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 6 citations in OpenAlex.
- Elucidating the Mechanism of Xiaoqinglong Decoction in Chronic Urticaria Treatment: An Integrated Approach of Network Pharmacology, Bioinformatics Analysis, Molecular Docking, and Molecular Dynamics Simulations.Current computer-aided drug design · 2026Article
- Mechanism of action of M-XQLD treatment for asthma: role of STARD13 in Th17 suppression.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- Traditional Chinese Medicine for Pediatric Allergic Diseases.Current allergy and asthma reports · 2025Review
- Efficacy of β2-adrenergic receptor agonist combined with corticosteroid in the treatment of children with cough variant asthma.World journal of clinical cases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effect of modified Xiaoqinglong Decoction on cough variant asthma (CVA) and immunological functioning in children.
methodsIn this is retrospective analysis, 122 children with CAV admitted to our hospital from Mar. 2021 to Mar. 2022 were divided into an observation group (n=61) and a control group (n=61) according to treatment methods. The control group received fluticasone propionate inhalation aerosol, and the observation group additionally received Xiaoqinglong Decoction. The therapeutic efficacy in the two groups was compared after 8 weeks of treatment. The comparison indictors included scores of daytime and nighttime cough, pulmonary function, fractional exhaled nitric oxide (FeNO), eosinophil count, inflammatory response (interleukin-4 (IL-4), tumor necrosis factor-α (TNF-α) and macrophage inflammatory protein ((MIP)-1α), immunoglobulin (Ig)) level and adverse reactions.
resultsThe overall response rate of children with CVA in the observation group was higher than that in the control group (
conclusionThe modified Xiaoqinglong Decoction has a conspicuous effect on children with CVA. It helps to reduce cough symptoms, improve pulmonary function, reduce inflammatory response and improve immunological functioning of children.
Indexed as
Identifiers
36915768PMC10006781W4324129432What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.